KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER a Libor USTOHAL. CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC. In ESCP PRAGUE SYMPOSIUM 2022. 2022. Dostupné z: https://dx.doi.org/10.1007/s11096-022-01521-5.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
Název anglicky CLOZAPINE AUGMENTATION WITH LONG-ACTING INJECTABLE ANTIPSYCHOTICS - EXPERIENCES IN THE CZECH REPUBLIC
Autoři KOTOLOVÁ, Hana, Martina NOVÁKOVÁ, Eliška NOVÁKOVÁ, Tomáš HAMMER a Libor USTOHAL.
Vydání ESCP PRAGUE SYMPOSIUM 2022, 2022.
Další údaje
Typ výsledku Konferenční abstrakt
Utajení není předmětem státního či obchodního tajemství
WWW 50th ESCP Symposium on Clinical Pharmacy, Polypharmacy and ageing - highly individualized, interprofessional, person-centered care. Int J Clin Pharm 44, 1464–1566 (2022). https://doi.org/10.1007/s11096-022-01521-5
Organizační jednotka Farmaceutická fakulta
Doi http://dx.doi.org/10.1007/s11096-022-01521-5
Klíčová slova anglicky Clozapine, augmentation, long-acting injectable antipsychotics
Příznaky Mezinárodní význam
Změnil Změnila: JUDr. Sabina Krejčiříková, učo 383857. Změněno: 10. 5. 2023 15:59.
Anotace
Clozapine is the drug of choice for drug-resistant schizophrenia, in which a combination of two antipsychotics with different mechanisms of action had no therapeutic effect. However, many patients have a continuing lack of response to treatment, so clozapine is combined with other psychotropic drugs. In the case of a clozapine-resistant patient who is in addition nonadherent to therapy, augmentation of clozapine with long-acting injectable antipsychotics (LAI APs) is offered. This combination is not yet widely used due to the possible occurrence of side effects (blood dyscrasias, weight gain, hyperglycemia, etc.). Experience with the combination of clozapine and LAI APs suggests that patients who are nonadherent and resistant to clozapine therapy could benefit from this treatment, although the amount of clinical data is currently low. Therefore, augmentation of clozapine with LAI APs should be individualized, based on sufficient medical experience.
VytisknoutZobrazeno: 23. 7. 2024 21:30